Oblique Therapeutics

Executive Summary

Oblique Therapeutics is a Swedish biotechnology company pioneering novel antibody therapeutics for pain management and aggressive metastatic cancers. Founded in 2015 and based in Gothenburg, the company leverages its proprietary AbiProt® platform to discover antibodies against traditionally challenging, difficult-to-drug targets. The platform enables targeting of G protein-coupled receptors (GPCRs) and ion channels, which are key in pain and cancer pathways but have been largely inaccessible to conventional antibody discovery. Oblique’s focus on these high-value targets positions it to address significant unmet medical needs, potentially offering safer and more effective alternatives to existing small molecules or biologics. As a private, early-stage company, Oblique Therapeutics remains in the preclinical development phase. Its success hinges on advancing its lead programs into clinical trials and securing partnerships to validate the AbiProt platform’s utility. The company’s innovative approach to undruggable targets provides a strong competitive edge, but it faces typical risks of drug development, including technical and regulatory hurdles. With no disclosed funding rounds or valuation, Oblique’s near-term progress will depend on in-house resources or external collaborations. Overall, the company represents a high-risk, high-reward opportunity in the antibody therapeutics space, with potential catalysts in platform validation and early clinical data expected within the next 18–24 months.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Advancement to IND-Enabling Studies40% success
• 2026–2027Pharmaceutical Partnership or Licensing Deal for AbiProt Platform30% success
• Q2 2026Publication or Presentation of Preclinical Data in Pain Indication60% success